Mostrar el registro sencillo del ítem
dc.contributor.author
Miller, Suellen
dc.contributor.author
Burke, Thomas
dc.contributor.author
Belizan, Jose
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.contributor.author
Fuchtner, Carlos
dc.contributor.author
Lalonde, Andre
dc.contributor.author
Malhorta, Jaideep
dc.date.available
2020-01-13T14:53:02Z
dc.date.issued
2017-09
dc.identifier.citation
Miller, Suellen; Burke, Thomas; Belizan, Jose; Fuchtner, Carlos; Lalonde, Andre; et al.; Tranexamic acid for post-partum haemorrhage in the WOMAN trial; Elsevier Science Inc; Lancet; 390; 10102; 9-2017; 1583
dc.identifier.issn
0140-6736
dc.identifier.uri
http://hdl.handle.net/11336/94487
dc.description.abstract
As clinicians and researchers of post-partum haemorrhage, we appreciate the clinical trial of tranexamic acid1 and applaud the researchers and results. We want to emphasise the importance of the addition of tranexamic acid to other technologies and strategies to form a complete comprehensive package for post-partum haemorrhage (or emergency post-partum haemorrhage bundle),2 which begins at the community level and proceeds, with attention to context, through primary health care to the referral-hospital level. As the authors note, tranexamic acid was tested at higher-level facilities (ie, secondary and tertiary hospitals) with providers not only able to give intravenous injections, but who were skilled enough (and equipped) to deliver a 1 mL/min dose of 1 g tranexamic acid, do hysterectomy or laparotomy, and give blood transfusions. Furthermore, the findings suggested early (<3 h) treatment with tranexamic acid, which is not always possible given the distances and delays women face in the settings of the community or primary health care. It could be some time before the bioavailability and correct dose of alternative routes have been trialled. For now in the setting of the community or primary health care, in which intravenous injections are neither safe nor feasible, and in higher-level facilities, in which a woman could arrive more than 3 h after the haemorrhage starts, a comprehensive continuum of care for post-partum haemorrhage is needed.3 At lower-level health-care facilities (ie, primary health care and dispensaries) the uterine balloon tamponade (as a packaged kit)4 and non-pneumatic antishock garment5 could save lives and buy time for referral and transportation delays. These interventions should be used together when necessary (in cases of shock) and should both decrease blood loss and cause clot formation, so that they can be effective with tranexamic acid. SM holds a faculty position at the University of California, San Francisco, which holds the right to the trademark LifeWrap (one brand of NASG) and has licensed this trademark to the BlueFuzion Group. BlueFuzion Group pays the University of California, San Francisco a royalty of 2·5% for the use of the trademark LifeWrap. All other authors declare no competing interests.
dc.format
application/pdf
dc.language.iso
eng
dc.publisher
Elsevier Science Inc
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.rights
info:eu-repo/semantics/openAccess
dc.rights.uri
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.subject
Tranexamic acid
dc.subject
post-partum haemorrhage
dc.subject.classification
Otras Ciencias de la Salud
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.subject.classification
Ciencias de la Salud
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.subject.classification
CIENCIAS MÉDICAS Y DE LA SALUD
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.title
Tranexamic acid for post-partum haemorrhage in the WOMAN trial
dc.type
info:eu-repo/semantics/article
dc.type
info:ar-repo/semantics/artículo
dc.type
info:eu-repo/semantics/publishedVersion
dc.date.updated
2019-12-27T13:59:07Z
dc.journal.volume
390
dc.journal.number
10102
dc.journal.pagination
1583
dc.journal.pais
Países Bajos
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.journal.ciudad
Amsterdam
dc.description.fil
Fil: Miller, Suellen. University of California; Estados Unidos
dc.description.fil
Fil: Burke, Thomas. Massachusetts General Hospital; Estados Unidos
dc.description.fil
Fil: Belizan, Jose. Instituto de Efectividad Clínica y Sanitaria; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
dc.description.fil
Fil: Fuchtner, Carlos. International Federation Of Gynecology And Obstetrics; Bolivia
dc.description.fil
Fil: Lalonde, Andre. McGill University; Canadá. University of Ottawa; Canadá
dc.description.fil
Fil: Malhorta, Jaideep. Rainbow Hospitals; India
dc.journal.title
Lancet
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/url/https://www.sciencedirect.com/science/article/pii/S014067361732408X
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/doi/http://dx.doi.org/10.1016/S0140-6736(17)32408-X
Archivos asociados